Cassava Sciences, Inc. (SAVA)

Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing innovations to treat neurodegenerative diseases, with a particular emphasis on Alzheimer's disease. Founded in 1998 and headquartered in Austin, Texas, the company is led by CEO Remi Barbier. Cassava Sciences is recognized for its work on simufilam, a promising drug candidate aimed at improving the treatment of Alzheimer's by targeting both cognitive and behavioral symptoms. As a publicly traded company, Cassava Sciences is listed on the NASDAQ under the ticker symbol SAVA. The company has been garnering interest due to its novel approach to addressing Alzheimer's, though it's important to note that, as a clinical-stage company, its revenue primarily stems from research and development activities rather than product sales. Cassava Sciences' work is highly relevant to those interested in advancements in Alzheimer's research and potential treatments for this devastating disease.